Career:

• Bar admission: 2005
• Graduate from the University of Paris I (Panthéon-Sorbonne), Paris II (Pantheon-Assas) and the University of “La Sapienza” (Rome)
• Partner at Armfelt (2011)
• Partner at ADVANT Altana (2016)

Areas of expertise:

• Product Liability
• Health Law
• Intellectual property
• Unfair competition

Practice Areas:

• advises, assists and represents both French and international industrial players, particularly in the pharmaceutical sector, in product liability matters before various jurisdictions (civil, administrative and criminal). He notably handles complex serial claims and has developed a strong expertise in healthcare class actions and notably represents a leading pharmaceutical group in the first two pharmaceutical class actions in France. His practice has a decidedly international bent, as he manages and coordinates mass disputes on an international level.
• assists pharmaceutical industries in all matters relating to intellectual property law (with particular focus on fields such as patents, trademarks, know-how and employee’s invention) and has developed a significant practice in the field of customs legislation related to falsified / counterfeit medicinal products.
• he is also regularly consulted in the context of reflexions and proposals concerning draft bills or the modification of the French legal system.

Languages:

• French
• English
• Italian

Distinctions:

• Best Lawyers – reconnu depuis 2020 (Biotechnology and Life Sciences Practice | Intellectual Property Law | Litigation | Product Liability Litigation)
• Chambers Europe 2023 – Pharma/Life Sciences: Product Liability – France – Band 2
• Legal 500 EMEA 2022 – Secteurs et Industries : Santé & Sciences de la Vie – Tier 1 (Leading Individuals)
• Legal 500 EMEA 2022 – Propriété Intellectuelle : Brevets – Tier 4
• Option Droit & Affaires 2022 – Contentieux : Contentieux des produits défectueux et des sinistres – 1 étoile
• Décideurs (Leaders League) 2022 – Risques industriels & contentieux de la responsabilité : Responsabilité du fait des produits – Excellent
• Décideurs (Leaders League) 2023 – Propriété Industrielle – Brevets : Contentieux – Forte notoriété
• Décideurs (Leaders League) 2023 – Propriété Industrielle – Gestion de portefeuilles de marques, dessins et modèles – Forte notoriété
• Décideurs (Leaders League) 2023 – Propriété Industrielle – Marques : Contentieux – Forte notoriété
• Décideurs (Leaders League) 2022 – Brevets : contentieux pharma, biotechs et sciences de la vie – Forte notoriété
• Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Responsabilité du fait des produits – Incontournable
• Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Droit pénal de la santé – Excellent
• Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Santé électronique – Forte notoriété
• Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Contrats de licensing, Co-développement et R&D  – Forte notoriété

Publications:

• “Implant files’: Paris administrative court places cursor between freedom of speech and business secrecy”, Lexology, January 2021
• “Baclofene saga continues”, Lexology, December 2020
• “Suspension of decision granting Baclocur market authorisation when decision is based on compromise rather than scientific knowledge”, Lexology, September 2020
• “COVID-19: French Administrative Supreme Court rulings on interim measures challenging government policies”, Lexology, April 2020